Classifications

• • C—CHEMISTRY; METALLURGY
  • C40—COMBINATORIAL TECHNOLOGY
  • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
  • C40B40/00—Libraries per se, e.g. arrays, mixtures
  • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
  • C12N15/1034—Isolating an individual clone by screening libraries
  • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2795/00—Bacteriophages
  • C12N2795/00011—Details
  • C12N2795/10011—Details dsDNA Bacteriophages
  • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

• the present invention relates to methods for displaying (poly)peptides/proteins on the surface of bacteriophage particles by attaching the (poly)peptide/proteins via disulfide bonds.
• fusions to gene HI protein (Parmley & Smith, 1988) or fragments thereof (Bass et al., 1990), and gene VIE protein (Greenwood et al., 1991).
• gene VI has been used (Jespers et al., 1995), and recently, a combination of gene VII and gene IX has been used for the display of Fv fragments (Gao et al., 1999).
• phage display has also been achieved on phage lambda.
• gene V protein Maruyama et al., 1994
• gene J protein, and gene D protein (Sternberg & Hoess, 1995; Mikawa et al., 1996) have been used.
• fusion proteins comprising at least part of a phage coat protein and a foreign (poly)peptide/protein.
• gene HI as partner for peptides/proteins to be displayed, this leads to several problems.
• the expression product of gene HI is toxic to the host cell, which requires tight regulation of gene JJJ fusion proteins.
• expression of gene HI products can make host cells resistant to infection with helper phage required for the production of progeny phage particles.
• recombination events between gene HI fusion constructs and wild type copies of gene HI lead to undesired artefacts.
• the size of the vectors comprising the nucleic acid sequences is rather larger, leading to a decrease in transformation efficiency. Transformation efficiency, however, is a crucial factor for the production of very large libraries.
• the (poly)peptide/protein are usually recloned into expression vectors in order to remove the phage coat protein fusion partner, or in order to create new fusion proteins such as by fusion to enzymes for detection or to multimerisation domains. It would be advantageously to have a system which would allow direct expression without recloning, and direct coupling of the (poly)peptide/protein to other moieties.
• the technical problem underlying the present invention is to develop a simple, reliable system which enables the presentation of (poly)peptides/proteins on phage particles without the need to use fusion proteins with phage coat proteins. Additionally, there is a need for a method which allows to recover tightly binding (poly)peptides/proteins in a more reliable way.
• the present invention allows to easily create and screen large libraries of (poly)peptides/proteins displayed on the surface of bacteriophage particles.
• the technical approach of the present invention i.e. linking (poly)peptides/proteins by disulfide bonds to the surface of phage particles, is neither provided nor suggested by the prior art.
• the present invention relates to a method for displaying a (poly)peptide/protein on the surface of a bacteriophage particle comprising: causing or allowing the attachment of said (poly)peptide/protein after expression to a member of the protein coat of said bacteriophage particle, wherein said attachment is caused by the formation of a disulfide bond between a first cysteine residue comprised in said (poly)peptide/protein and a second cysteine residue comprised in said member of the protein coat.
• the term "bacteriophage” relates to bacterial viruses forming packages consisting of a protein coat containing nucleic acid required for the replication of the phages.
• the nucleic acid may be DNA or RNA, either double or single stranded, linear or circular.
• Bacteriophage such as phage lambda or filamentous phage (such as M13, fd, or fl) are well known to the artisan of ordinary skill in the art.
• the term "bacteriophage particles” refers to the particles according to the present invention, i.e. to particles displaying a (poly)peptide/protein via a disulfide bonds.
• nucleic acid sequences contained in bacteriophages or bacteriophage particles relates to nucleic acid sequences or vectors having the ability to be packaged by bacteriophage coat proteins during assembly of bacteriophages or bacteriophage particles.
• nucleic acid sequences or vectors are derived from naturally occurring genomes of bacteriophage, and comprise for example, in the case of filamentous phage, phage and phagemid vectors.
• the latter are plasmids containing a packaging signal and a phage origin of replication in addition to plasmid features.
• (poly)peptide relates to molecules consisting of one or more chains of multiple, i. e. two or more, amino acids linked via peptide bonds.
• protein refers to (poly)peptides where at least part of the (poly)peptide has or is able to acquire a defined three-dimensional arrangement by forming secondary, tertiary, or quaternary structures within and/or between its (poly)peptide chain(s).
• This definition comprises proteins such as naturally occurring or at least partially artificial proteins, as well as fragments or domains of whole proteins, as long as these fragments or domains are able to acquire a defined three-dimensional arrangement as described above.
• Examples of (poly)peptides/proteins consisting of one chain are single-chain Fv antibody fragments, and examples for (poly)peptides/proteins consisting of more chains are Fab antibody fragments.
• the display format corresponds to the conventional display set-up with the C-terminus being genetically fused to the member of the phage coat protein.
• the display format can be reverted as in the pJuFO system of Crameri & Suter referred to above.
• the term "surface of a bacteriophage particle” refers to the part of a bacteriophage particle which is in contact with the medium the particle is contained in and which is accessible. The surface is determined by the proteins being part of the phage coat (the members of the protein coat of the particle) which is assembled during phage production in appropriate host cells.
• the term “after expression” refers to the situation that nucleic acid encoding said (poly)peptide/protein is expressed in a host cell prior to attachment of the (poly)peptide/protein to said coat, in contrast to approaches where nucleic acid encoding fusion proteins with bacteriophage coat proteins are being expressed.
• nucleic acid encoding said (poly)peptide/protein and the step of causing or allowing the attachment may be performed in separated steps and/or environments. Preferably, however, expression and the step of causing or allowing the attachment are being performed sequentially in an appropriate host cell.
• the term "wherein said attachment is caused by the formation of a disulfide bond" refers to a situation, wherein the disulfide bond is responsible for the attachment, and wherein no interaction domain for interaction with a second domain present in the (poly)peptide/protein has been recombinantly fused to said member of the protein coat, as for example in the case of the pJuFo system (Crameri & Suter, 1993).
• the bacteriophage particle displaying the (poly)peptide/protein contains a nucleic acid sequence encoding the (poly)peptide/protein.
• nucleic acid molecules encoding a (poly)peptide/protein for construction of vectors comprising said nucleic acid molecules, for introduction of said vectors into appropriately chosen host cells, for causing or allowing the expression of said (poly)peptides/proteins are well-known in the art (see, e.g., Sambrook et al., 1989; Ausubel et al., 1999; Ge et al, 1995).
• the present invention relates to a method, wherein said second cysteine residue is present at a corresponding amino acid position in a wild type coat protein of a bacteriophage.
• the present invention relates to a method, wherein said member of the protein coat is a wild type coat protein of a bacteriophage.
• wild type coat protein refers to those proteins forming the phage coat of naturally occurring bacteriophages.
• said wild type proteins are gene HI protein (pHI), gene VI protein (pVI), gene VH protein (pVH), gene VHI protein (pVHI), and gene IX protein (pIX).
• the sequences, including the differences between the closely related members of the filamentous bacteriophages such as fl, fd, and M13, are well known to one of ordinary skill in the art (see, e.g., Kay et al., 1996).
• said member of the protein coat is a truncated variant of a wild type coat protein of a bacteriophage, wherein said truncated variant comprises at least that part of said wild type coat protein causing the incorporation of said coat protein into the protein coat of the bacteriophage particle.
• truncated variant refers to proteins derived from the wild type proteins referred to above which are modified by deletion of at least part of the wild type sequences. This comprises variants such as truncated gene HI protein variants which have been found in bacteriophage mutants (Crissman & Smith, 1984) or which have been generated in the course of standard phage display methods (e.g. Bass et al., 1990; Krebber, 1996).
• said truncated variant may consist, or include, the C-terminal domain of the gene HI protein.
• a detection tag may be fused to the variant, and an assay may be set up to determine whether the variant is incorporated into the phage coat of bacteriophage particles formed in the presence of the variant.
• an assay may be set up to determine whether the variant is incorporated into the phage coat of bacteriophage particles formed in the presence of the variant.
• a cysteine residue may become available which in the wild type protein was forming a disulfide bond with a second cysteine comprised in the deleted part.
• said member of the protein coat is a modified variant of a wild type coat protein of a bacteriophage, wherein said modified variant is capable of being incorporated into the protein coat of the bacteriophage particle.
• Methods for achieving modification of a wild type protein according to the present invention are well-known to one of ordinary skill in the art, and involve standard cloning and/or mutagenesis techniques.
• Methods for the construction of nucleic acid molecules encoding a modified variant of a wild type protein used in a method according to the present invention for construction of vectors comprising said nucleic acid molecules, including the construction of phage and/or phagemid vectors, for introduction of said vectors into appropriately chosen host cells, for causing or allowing the expression of said modified protein are well-known in the art (see, e.g., Sambrook et al., 1989; Ausubel et al., 1999; Kay et al., 1996).
• a detection tag may be fused to the variant, and an assay may be set up to determine whether the variant is capable or being incorporated into the phage coat of bacteriophage particles formed in the presence of the variant.
• said second cysteine residue is not present at a corresponding amino acid position in a wild type coat protein of a bacteriophage.
• said second cysteine has been artificially introduced into a wild type coat protein of a bacteriophage.
• nucleic acid encoding a wild type coat protein may be manipulated by standard procedures to introduce a cysteine codon creating a nucleic acid sequence encoding a modified coat protein, wherein a cysteine residue is artificially introduced by insertion into, or addition of said cysteine residue to, said at least part of a wild type or modified coat protein, or by substitution of an amino acid residue comprised in said at least part of a wild type or modified protein by said cysteine residue, or by fusion of said at least part of a wild type or modified coat protein with a (poly)peptide/protein comprising said second cysteine residue, or by any combination of said insertions, additions, substitutions or fusions.
• said second cysteine has been artificially introduced into a truncated variant of a wild type coat protein of a bacteriophage.
• said second cysteine has been artificially introduced into a modified variant of a wild type coat protein of a bacteriophage.
• Methods for achieving the artificial introduction according to the present invention are well- known to one of ordinary skill in the art, and involve standard cloning and/or mutagenesis techniques.
• Methods for the construction of nucleic acid molecules encoding a modified variant of a wild type protein used in a method according to the present invention, for construction of vectors comprising said nucleic acid molecules, for introduction of said vectors into appropriately chosen host cells, for causing or achieving the expression of said fusion proteins are well-known in the art (see, e.g., Sambrook et al., 1989; Ausubel et al., 1999).
• the present invention relates to a method, wherein said second cysteine is present at, or in the vicinity of, the C- or the N-terminus of said member of the phage coat of said bacteriophage particle.
• said bacteriophage is a filamentous bacteriophage.
• Filamentous bacteriophage such as M13, fd, or fl are well known to the artisan of ordinary skill in the art.
• a method is particularly preferred, wherein said member of the protein coat of the bacteriophage particle is or is derived from the wild type coat protein pHI. Further preferred is a method, wherein said member of the protein coat of the bacteriophage particle is or is derived from the wild type coat protein pIX.
• the term "is derived” refers to a modification, wherein the modified protein is capable of being incorporated into the protein coat of the bacteriophage particle.
• those parts of the modified protein corresponding to the wild type protein exhibit an amino acid identity exceeding about 70%, preferably about 80%, most preferably about 90% compared to the corresponding wild type sequence.
• the method comprises:
• causing or allowing the expression describes cultivating host cells under conditions such that nucleic acid sequence is expressed.
• Methods for construction of nucleic acid molecules encoding a (poly)peptide/protein according to the present invention, for construction of vectors comprising said nucleic acid molecules, for introduction of said vectors into appropriately chosen host cells, for causing or allowing the expression of (poly)peptides/proteins are well-known in the art (see, e.g., Sambrook et al., 1989; Ausubel et al., 1999).
• said (poly)peptide/protein comprises an immunoglobulin or a functional fragment thereof.
• immunoglobulin is used as a synonym for "antibody”.
• functional fragment refers to a fragment of an immunoglobulin which retains the antigen-binding moiety of an immunoglobulin.
• Functional immunoglobulin fragments according to the present invention may be Fv (Skerra & Pl ⁇ ckthun, 1988), scFv (Bird et al., 1988; Huston et al., 1988), disulfide-linked Fv (Glockshuber et al., 1992; Brinkmann et al., 1993), Fab, F(ab') fragments or other fragments well-known to the practitioner skilled in the art, which comprise the variable domain of an immunoglobulin or immunoglobulin fragment. Particularly preferred is an scFv or Fab fragment.
• the present invention relates to a nucleic acid sequence encoding a modified variant of a wild type coat protein of a bacteriophage, wherein said modified variant consists of:
• a modified variant obtained by substitution of an amino acid residue in a wild type coat protein sequence by a cysteine residue may be regarded as a variant composed of two parts of said wild type protein linked by an additional cysteine residue.
• variants of a wild type coat protein comprising several mutations compared to the wild type sequence may be regarded as being composed of several wild type parts, wherein the individual parts are linked by the mutated residues.
• said variant may also result from the addition of up to six residues, including a cysteine residue, to either C- and or N-terminus of the wild type coat protein.
• nucleic acid sequence encoding a modified variant of a wild type coat protein of a bacteriophage, wherein said modified variant consists of:
• peptides comprising at least five histidine residues (Hochuli et al., 1988), which are able to bind to metal ions, and can therefore be used for the purification of the protein to which they are fused (Lindner et al., 1992).
• additional moieties such as the commonly used c-myc and FLAG tags (Hopp et al., 1988; Knappik & Pl ⁇ ckthun, 1994), or the Strep-tag (Schmidt & Skerra, 1994; Schmidt et al., 1996).
• the modified variant may further comprise amino acid residues required for cloning, for expression, or protein transport.
• Amino acid residues required for cloning may include residues encoded by nucleic acid sequences comprising recognition sequences for restriction endonucleases which are incorporated in order to enable the cloning of the nucleic acid sequences into appropriate vectors.
• Amino acid residues required for expression may include residues leading to increased solubility or stability of the (poly)peptide/protein.
• Amino acid residues required for protein transport may include signalling sequences responsible for the transport of the modified variant to the periplasm of E.coli, and/or amino acid residues facilitating the efficient cleavage of said signalling sequences. Further amino acid residues required for cloning, expression, protein transport, purification and/or detection purposes referred to above are numerous moieties well known to the practitioner skilled in the art.
• the present invention relates to a vector comprising a nucleic acid sequence according to the present invention.
• the vector further comprises one or more nucleic acid sequences encoding a (poly)peptide/protein comprising a second cysteine residue.
• said (poly)peptide/protein comprises an immunoglobulin or a functional fragment thereof.
• the vector comprises one nucleic acid sequence encoding the VH and VL domains linked by a (poly)peptide linker, and in the case of Fab antibody fragments, the vector comprises two nucleic acid sequences encoding the VH-CH and the VL-CL chains.
• the present invention relates to a host cell containing a nucleic acid sequence according to the present invention or a vector according to the present invention.
• the term "host cell” may be any of a number commonly used in the production of heterologous proteins, including but not limited to bacteria, such as Escherichia coli (Ge et al., 1995), or Bacillus subtilis (Wu et al., 1993), fungi, such as yeasts (Horwitz et al., 1988; Ridder et al., 1995) or filamentous fungus (Nyyss ⁇ nen et al., 1993), plant cells (Hiatt & Ma, 1993; Whitelam et al., 1994), insect cells (Potter et al., 1993; Ward et al., 1995), or mammalian cells (Trill et al., 1995).
• bacteria such as Escherichia coli (Ge et al., 1995), or Bacillus subtilis (Wu et al., 1993)
• fungi such as yeasts (Horwitz et al., 1988; Ridder et al.
• the present invention relates to a modified variant of a wild type bacteriophage coat protein encoded by a nucleic acid sequence according to the present invention, a vector according to the present invention or produced by a host cell according to the present invention.
• the present invention relates to a bacteriophage particle displaying a
• (poly)peptide/protein on its surface obtainable by a method comprising: causing or allowing the attachment of said (poly)peptide/protein after expression to a member of the protein coat of said bacteriophage particle, wherein said attachment is caused by the formation of a disulfide bond between a first cysteine residue comprised in said
• the present invention relates to a bacteriophage particle displaying a (poly)pep tide/protein attached to its surface, wherein said attachment is caused by the formation of a disulfide bond between a first cysteine residue comprised in said (poly)peptide/protein and a second cysteine residue comprised in a member of the protein coat of said bacteriophage particle.
• the bacteriophage particle further contains a vector comprising one or more nucleic acid sequences encoding said (poly)peptide/protein.
• the bacteriophage particle contains a vector according to the present invention, wherein said vector comprises a nucleic acid sequence encoding a modified wild type bacteriophage coat protein and furthermore one or more nucleic acid sequences encoding a (poly)peptide/protein and most preferably comprising at least a functional domain of an immunoglobulin.
• the present invention relates to a diverse collection of bacteriophage particles according to the present invention, wherein each of said bacteriophage particles displays a (poly)peptide/protein out of a diverse collection of (poly)peptides/proteins.
• a "diverse collection of bacteriophage particles” may as well be referred to as a “library” or a “plurality of bacteriophage particles”. Each member of such a library displays a distinct member of the library.
• the term "diverse collection” refers to a collection of at least two particles or molecules which differ in at least part of their compositions, properties, and/or sequences.
• a diverse collection of (poly)peptides/proteins is a set of (poly)peptides/proteins which differ in at least one amino acid position of their sequence.
• Such a diverse collection of (poly)peptides/proteins can be obtained in a variety of ways, for example by random mutagenesis of at least one codon of a nucleic acid sequence encoding a starting (poly)peptide/protein, by using error-prone PCR to amplify a nucleic acid sequence encoding a starting (poly)peptide/protein, or by using mutator strains as host cells in a method according to the present invention.
• a "diverse collection of bacteriophage particles” may be referred to as a library or a plurality of bacteriophage particles. Each member of such a library displays a distinct member of the library.
• the invention relates to a method for obtaining a (poly)peptide/protein having a desired property comprising:
• the term "desired property” refers to a predetermined property which one of the (poly)peptides/proteins out of the diverse collection of (poly)peptides/proteins should have and which forms the basis for screening and/or selecting the diverse collection.
• properties comprise properties such as binding to a target, blocking of a target, activation of a target-mediated reaction, enzymatic activity, and further properties which are known to one of ordinary skill.
• one of ordinary skill will be able to identify format and necessary steps for performing screening and/or selection.
• Most preferred is a method , wherein said desired property is binding to a target of interest.
• Said target of interest can be presented to said diverse collection of bacteriophage particles in a variety of ways well known to one of ordinary skill, such as coated on surfaces for solid phase biopanning, linked to particles such as magnetic beads for biopanning in solution, or displayed on the surface of cells for whole cell biopanning or biopanning on tissue sections.
• Bacteriophage particles having bound to said target can be recovered by a variety of methods well known to one of ordinary skill, such as by elution with appropriate buffers, either by using a pH- or salt gradient, or by specific elution using soluble target.
• the method for obtaining a (poly)peptide/protein further comprises:
• step (bb) eluting bacteriophage particles not binding to the target of interest; (be) eluting bacteriophage particles binding to the target of interest by treating the complexes of target of interest and bacteriophages binding to said target of interest formed in step (ba) under reducing conditions.
• the disulfide bonds are cleaved, thus allowing to recover the specific bacteriophage particles for further rounds of biopanning and/or for identification of the (poly)peptide/proteins specifically binding to said target.
• Figure la Vector map of construct pMorphX7-hag2-LH.
• Figure lb Vector sequence of pMorphX7-hag2-LH.
• Figure 2 Vector sequence of pTFT74-Nl-hag-HIPM
• Figure 3 Vector sequence of pQE60-MacI
• Figure 4 Specific binding of scFv displayed on non-engineered phages.
• Phages derived from constructs pMorphX7-MacI5-LCH, pMorphX7-MacI5-LHC and pMorphX7-MacI5-LH were produced by standard procedures and pre-incubated in PBSTM either with 5 mM DTT (+ DTT) or without DTT. 5 ⁇ g/well of specific antigen (Mad, dark columns) as well as unspecific control antigen (BSA, light columns) were coated onto Maxisorp Nunc-Immuno microtiter plates and incubated with lx 10 phages/well, respectively. Bound phages were detected via anti-M13-HRP conjugate and BM blue soluble substrate. Phages derived from conventional phage display vector pMorphl3-MacI5 were
• Figure 5 Specific binding of scFv displayed on non-engineered phages.
• Phages derived from constructs pMorphX7-hag2-LCH, pMorphX7-hag2-LHC and pMorphX7-hag2-LH were produced by standard procedures and pre-incubated in PBSTM either with 5 mM DTT (+ DTT) or without DTT. 5 ⁇ g/well of specific antigen (Nl-hag, dark columns) as well as unspecific control antigen (BSA, light columns) were coated onto Maxisorp Nunc-Immuno microtiter plates and incubated with lx 10 phages/well, respectively. Bound phages were detected via anti-M13-HRP conjugate and BM blue soluble substrate.
• Phages derived from conventional phage display vector pMorphl3-hag2 were used ⁇ as control (3x 10 phages/well). Experimental details are given in Example 1.
• Figure 6a Vector map of construct pBR-C-glll.
• Figure 6b Sequence of expression cassette for full length pill with an N-terminal cysteine residue (C-glll).
• Figure 6c Sequence of expression cassette for truncated pill with an N-terminal cysteine residue (C-gHICT).
• Figure 7a Vector map of construct pMorphl8-C-gIII- hag2-LHC.
• Figure 7b Vector sequence of pMorphl8-C-gIII-hag2-LHC.
• Figure 8 Detection of scFv MacI-5 displayed on engineered phages - Two-vector system.
• Phages derived from constructs pMo ⁇ hl8-C-gHI-hag2-LHC (lanes 1 - 8; 7A), pMo ⁇ hl8-C- gm-ABl.l-LHC (lanes 1, 2, 5 and 6; 7B) and pMo ⁇ hl8-C-gHI-MacI-5-LHC (lanes 3, 4, 7 and 8; 7B) were produced by standard procedures. 1-5 x 10 10 phages were pre-incubated in PBS with DTT (lanes 1, 2, 5 and 6; 7A and lanes 1 - 4; 7B) or without DTT (lanes 3, 4, 7 and 8; 7A and lanes 5 - 8; 7B).
• Figure 10 Specific binding of scFv displayed on engineered phages - Comparison of the different two-vector systems.
• Phages derived from constructs pMo ⁇ hX7-MacI-5-LHC / pBR-C-gHI (1), pM ⁇ hX7-MacI- 5-LHC / pBR-C-gHICT (2), P Mo ⁇ hX7-MacI-5-LHC / pUC-C-gHI (3), pM ⁇ hX7-Mad-5- LHC / pUC-C-gHICT (4), pMo ⁇ hX7-Mad-5-LHC (5), pM ⁇ hX7-Mad-5-LH (6) and the conventional phage display vector pM ⁇ hl3-MacI-5 (7) were produced by standard procedures.
• Figure 11 Specific binding of scFv displayed on engineered phages - Comparison of the one- and two- vector system.
• Phages derived from constructs pMo ⁇ hX7-MacI-5-LHC / pBR-C-gHI (1), pM ⁇ hX7-MacI- 5-LHC / pBR-C-gHICT (2), pMo ⁇ hl8-C-gIH-MacI-5-LHC (3), pM ⁇ hl8-C-gIHCT-MacI-5- LHC (4) and pMo ⁇ hX7-MacI-5-LHC (5) were produced by standard procedures.
• Figure 12 Specific binding of scFv displayed on engineered phages - Comparison of engineered gene III and gene IX proteins in the one-vector system.
• Phages derived from constructs pM ⁇ hl8-C-gIH-MacI-5-LHC (1), pMo ⁇ hl8-C-gIHCT- MacI-5-LHC (2), pM ⁇ hl8-C-gIX-Mad-5-LHC (3), pM ⁇ hX7-Mad-5-LHC (4) and the conventional phage display vector pMo ⁇ hl3-MacI-5 (5) were produced by standard procedures.
• Figure 13 Specific binding of scFv displayed on engineered phages - Impact of DTT.
• Phages derived from constructs pMo ⁇ hl8-C-gHI-MacI-5-LHC (1), pMo ⁇ hl8-C-gHICT- MacI-5-LHC (2), pM ⁇ hl8-C-gIX-Mad-5-LHC (3), pM ⁇ hX7-Mad-5-LHC (4) and the conventional phage display vector pMo ⁇ hl3-MacI-5 (5) were produced by standard procedures and pre-incubated in PBSTM either with 5 mM DTT (+) or without DTT (-).
• Figure 14 Specificity of selected scFvs - Panning of pre-selected pools against Nl-Macl.
• scFvs selected after two rounds of cys-display panning against antigen Nl-Macl from the K- chain (1-5) and the ⁇ -chain pool (6-8) were expressed according to standard procedures.
• 0.1 ⁇ g/well of milk powder (A), BSA (B), FITC-BSA (C, FTTC coupled to BSA), Nl-hag (D), Nl-Np50 (E) and Nl-Macl (Nl-Macl) was coated onto 384 well plates (Maxiso ⁇ ; Nunc) and incubated with 10 ⁇ l scFv solution, respectively.
• Bound scFvs were detected via a mixture of anti-Flag Ml, anti-Flag M2 and anti-mouse IgG-AP conjugate as well as AttoPhos fluorescence substrate (Roche #1484281). Each scFv was tested in quadruplicates and mean values are presented.
• Figure 15 Specificity of selected scFvs - Panning of pre-selected pools against Nl-Np50.
• scFvs selected after two rounds of cys-display panning against antigen Nl-Np50 (1-8) were expressed according to standard procedures.
• 0.1 ⁇ g/well of milk powder (A), BSA (B), FTTC- BSA (C, FTTC coupled to BSA), Nl-hag (D), Nl-Macl (E) and Nl-Np50 (Nl-Np50) was coated onto 384 well plates (Maxiso ⁇ ; Nunc) and incubated with 10 ⁇ l scFv solution, respectively.
• Bound scFvs were detected via a mixture of anti-Flag Ml, anti-Flag M2 and anti-mouse IgG-AP conjugate as well as AttoPhos fluorescence substrate (Roche #1484281). Each scFv was tested in quadruplicates and mean values are presented.
• Figure 16a Vector map of construct pMorphX10-Fab-MacI5-VL-LHC-VH-FS.
• Figure 16b Complete vector sequence of pMorphX10-Fab-MacI5-VL-LHC-VH-FS.
• Figure 17 Detection of Fab ICAM1-C8 displayed on engineered phages.
• Phages derived from constructs pM ⁇ hX10-Fab-ICAMlC8-VL-LHC-VH-MS / pBAD-SS- C-gHI (lanes 5,6,11,12), pM ⁇ hX10-Fab-ICAMlC8-VL-LHC-VH-MS (lanes 3,4,9,10) and pMo ⁇ hl8-Fab-ICAMlC8 (lanes 1,2,7,8) were produced by standard procedures. 1 x 10 10 phages were pre-incubated in PBS with DTT (lanes 1 - 6) or without DTT (lanes 7 - 12).
• Figure 18 Detection of Fab Macl-A8 displayed on engineered phages.
• Phages derived from constructs pMo ⁇ hX10-Fab-MacIA8-VL-LHC-VH-FS / pBAD-SS-C- gHI (lanes 5,6,11,12), pMo ⁇ hX10-Fab-MacIA8-VL-LHC-VH-FS (lanes 3,4,9,10) and pMo ⁇ hl8-Fab-MacIA8 (lanes 1,2,7,8) were produced by standard procedures. 1 x 10 10 phages were pre-incubated in PBS with DTT (lanes 1 - 6) or without DTT (lanes 7 - 12).
• Figure 19 Specific binding of Fabs displayed on engineered phages - Fab MacI-5.
• Example 2.2 5 ⁇ g/well of specific antigen (Nl-Macl) were coated onto Maxiso ⁇ Nunc-Immuno microtiter plates and incubated with lx 10 8 (light columns) and lx 10 9 (dark columns) phages per well. Bound phages were detected via anti-M13-HRP conjugate and BM blue soluble substrate. Each column represents the mean value of three independent phage preparations tested in duplicates. Experimental details are given in Example 2.2.
• Figure 20 Specific binding of Fabs displayed on engineered phages - Fab Macl-A8.
• Example 2.2 5 ⁇ g/well of specific antigen (Nl-Macl) were coated onto Maxiso ⁇ Nunc-Immuno microtiter plates and incubated with lx 10 9 (light columns) and lx 10 10 (dark columns) phages per well. Bound phages were detected via anti-M13-HRP conjugate and BM blue soluble substrate. Each column represents the mean value of three independent phage preparations tested in duplicates. Experimental details are given in Example 2.2.
• Figure 21 Specific binding of Fabs displayed on engineered phages - Fab ICAM1-C8.
• Example 2.2 5 ⁇ g/well of specific antigen (ICAM1, dark columns) or unspecific antigen (BSA, light columns) were coated onto Maxiso ⁇ Nunc- Immuno microtiter plates and incubated with lx 10 9 phages per well. Bound phages were detected via anti-M13-HRP conjugate and BM blue soluble substrate. Each column represents the mean value of one phage preparation tested in duplicates. Experimental details are given in Example 2.2.
• IAM specific antigen
• BSA unspecific antigen
• Figure 22 Specific binding of Fabs displayed on engineered phages - Impact of DTT.
• Phages derived from constructs pM ⁇ hX10-Fab-MacI5-VL-LHC-VH-FS / pBR-C-gHI (1), pM ⁇ hX10-Fab-MacI5-VL-C-VH-FS / pBR-C-gHI (2), pM ⁇ hX10-Fab-MacI5-VL-VH- CFS / pBR-C-gHI (3), P M ⁇ hX10-Fab-MacI5-VL-VH-LHC / pBR-C-gHI (4), pMo ⁇ hX9- Fab-MacI5-FS (5), and the conventional phage display vector pMo ⁇ hl8-Fab-MacI5 (6) were produced by standard procedures and pre-incubated in PBSTM either with 10 mM DTT (+) or without DTT (-).
• Example 2.2 5 ⁇ g/well of specific antigen (Nl-Macl, dark columns) as well as unspecific control antigen (BSA, light columns) were coated onto Maxiso ⁇ Nunc-Immuno microtiter plates and incubated with lx 10 9 phages respectively. Bound phages were detected via anti- M13-HRP conjugate and BM blue substrate. Each column represents the mean value of one phage preparation tested in duplicates. Experimental details are given in Example 2.2.
• Example 1 Display of (pol )pep tides/proteins on the surface of non-engineered filamentous bacteriophage particles via formation of disulfide bonds
• All vectors used are derivatives of the high copy phagemid pM ⁇ hX7-LH ( Figure la+b), a derivative of the pCAL vector series (WO 97/08320; Knappik et al., 2000).
• the expression cassette comprises the phoA signal sequence, a minimal binding site for the monoclonal antibody (mab) anti-FLAG Ml (Sigma #F-3040) (Knappik and Pl ⁇ ckthun, 1994), a single chain fragment (scFv), a short linker (PGGSG) and a 6x histidine tag (6His; Hochuli et al., 1988) ( Figure la).
• pMo ⁇ hX7-LCH and pMo ⁇ hX7-LHC have been generated by inserting oligonucleotide cassettes coding for Cys-6His and 6His-Cys, respectively, between the unique Ascl and HindJH sites of pMo ⁇ hX7-LH ( Figure la, Table 1). All vectors express soluble scFv not genetically fused to any phage coat protein.
• the conventional phage display vector pMo ⁇ hl3 which is based on the pCAL4 vector described in WO 97/08320 and expresses a fusion of an scFv to the C-terminal part of phage protein pIH was used as positive control.
• the scFvs have been exchanged between the respective vectors via the unique Xbal and EcoRI sites (c.f. Figure la).
• Clone hag2 was selected against a peptide from influenza virus hemagglutinine (aa 99-110 from hemagglutinine plus additional flanking aa (shown in italics, CAGPYDVPDYASLRSHH), and clone MacI-5 against a fragment (Mad) of human CR-3 alpha chain (SWISS-PROT entry PI 1215, aa 149 - 353 of human CR-3 alpha fused to a C-terminal sequence containing a 6x histidine tag).
• the corresponding antigens for ELISA and doped library experiments were obtained as follows.
• the hag2 specific antigen Nl-hag was produced using expression vector pTFT74-Nl-hag- HIPM, a derivative of vector pTFT74 (Freund et al., 1993) (Fig. 2).
• Nl-hag comprises aa 1-82 of mature gene HI protein of phage M13 containing an additional methionine residue at the N- terminus (Nl) fused to the amino acid sequence PYDVPDYASLRSHHHHHH (hag) comprising aa 99-110 from influenza virus hemagglutinine and a 6x histidine tag (in italics).
• Nl-hag Nl-hag expression, purification and refolding of Nl-hag was done as described (Krebber, 1996; Krebber et al., 1997).
• a purified fragment (Mad) of human CR-3 alpha chain (SWISS-PROT entry PI 1215) fused to a C-terminal 6x histidine tag was used.
• the expression cassette encodes an N-terminal methionine, amino acids 149 - 353 of human CR-3 alpha and amino acids IEGR ⁇ . This cassette is flanked by unique restriction sites _ ⁇ .sp ⁇ I and H dlH and can e.g.
• Phages were produced according to standard procedures using helper phage VCSM13 (Kay et al., 1996). Specific antigen or control antigen (BSA, Sigma #A7906) was coated for 12 h at 4°C at a concentration of 5 ⁇ g/well in PBS to ⁇ unc Maxiso ⁇ microtiter plates (# 442404).
• BSA Specific antigen or control antigen
• Phages were pre-incubated in PBSTM (PBS containing 5% skimmed milk powder and 0.1% Tween 20), either with or without 5 mM DTT, for 2 h at room temperature before they were applied to the ELISA well coated with antigen at a concentration of lx 10 phages per well except for pMo ⁇ hl3 which was used at a concentration of 3x 10 phages per well.
• PBSTM PBS containing 5% skimmed milk powder and 0.1% Tween 20
• pMo ⁇ hX7-hag2-LHC and pMo ⁇ hX7-Mad-5-LHC derived phages were mixed at ratios of 1:10 5 (pM ⁇ hX7-hag2-LHC panning) as well as 10 5 :1 (pM ⁇ hX7-Mad-5-LHC panning). Three rounds of panning were performed on the hag2 and MacI-5 specific antigen, respectively. Phages were prepared by standard procedure and pre -blocked by mixing 1: 1 with PBSTM (PBS, 5% skimmed milk powder, 0.1% Tween20) and incubation for 2 h at RT.
• PBSTM PBS, 5% skimmed milk powder, 0.1% Tween20
• Wells of a Nunc Maxiso ⁇ microtiter plate (#442404) were coated with specific antigen Nl-hag (as well as BSA) at a concentration of 5 ⁇ g/well in PBS overnight at 4°C, and subsequently blocked with 400 ⁇ l PBSM (PBS, 5% skimmed milk powder) for 2 h at RT.
• PBSM 5% skimmed milk powder
• 10 u pre-blocked phages were applied per well and incubated for 1 h at RT on a microtiter plate shaker. Phage solution was removed and wells were washed 3 times with PBST (PBS, 0.05% Tween20) and 3 times with PBS.
• Bound phages were eluted with 100 mM triethylamine according to standard protocols and used for infection of TGI cells. In addition, residual phages were eluted by direct infection of TGI added to the wells. After each round of panning on specific antigen the ratio of specific to unspecific phages was determined by analysing at least 46 independent infected cells via PCR. The PCR was performed according to standard protocols using single colonies as source of template and oligonucleotides specific for VH CDR3 and VL CDR3 of each scFv as primers.
• Example 2 Display of (poly)peptides/proteins on the surface of engineered filamentous bacteriophage particles via formation of disulfide bonds
• Example 1 described above shows that functional scFvs can be displayed on non-engineered phages via disulfide bonds.
• This system can be further improved, e.g. via engineering an exposed cysteine on a phage coat protein.
• One candidate phage coat protein is protein HI (pIH) which is composed of three domains Nl, N2 and pIHCT. Possible sites for positioning an unpaired cysteine residue are the linker regions between the domains or the exposed N- terminus of the domain or the pIHCT in a truncated pIH version.
• a further example would be phage coat protein IX (pLX) where the cysteine could e.g. be linked to the N-terminus of the full length protein.
• the cassettes for expression of such engineered proteins can be placed on the vector which is providing the scFv (one-vector system), or on a separate vector (two-vector system).
• Phage coat protein expression cassettes for the two-vector system were constructed as follows: Two different expression cassettes flanked by unique Nhel and HmdHI restriction sites at the ends were made positioning an unpaired cysteine residue at the exposed N-terminus of the Nl -domain of full length mature pIH (C-gHI) or at the N-terminus of the pIHCT domain of the truncated protein (amino acids 216 to 406 of protein pHI; C-gHICT) (Fig. 6b+c)).
• Both expression cassettes are under the control of the lac promotor/operator region and comprise the signal sequence ompA, amino acids DYCDIEF and the pIH or pIHCT ORF (complete amino acid sequences are given in Table 3). Plasmids expressing the modified pIH proteins were obtained by inserting these Nhel-HindHJ cassettes into plasmid pBR322 and pUC19 via the unique Nhel and HmdHI or Xbal and HmdHI sites, respectively. As an example, the vector map of pBR-C-glH is depicted in Figure 6a.
• the resulting plasmids, pBR-C-glH, pBR-C- gfflCT, pUC-C-gHI and pUC-C-gHICT, were co-transformed with pM ⁇ hX7-LHC phagemids expressing the modified scFv (Example 1) into E.coli TGI selecting for both antibiotic markers.
• the first expression cassette comprises the signal sequence ompA, amino acids DYCDIEF and the ORF for the respective phage coat protein or part thereof.
• the unpaired cysteine residue was linked to the exposed N-terminus of the Nl-domain of full length mature pIH (C-gHI), to the N-terminus of the truncated protein HJ (amino acids 216 to 406 of protein pHI; C-gHICT) and to the N-terminus of protein IX (C-glX), respectively (amino acid sequences are given in Table 4).
• the second expression cassette comprises the phoA signal sequence, the ORF of the respective scFv, a short linker (PGGSG), a 6x histidine tag (6His; Hochuli et al., 1988) and the single cysteine residue (see pMo ⁇ hX7-LHC, Table 1).
• a derivative of this vector, pM ⁇ h20-C-gIH-hag2-LHC, contains a unique EcoRI site at the 3' end of the scFv while the second site (between the ompA signal sequence and the gHI ORF) was deleted via silent PCR mutagenesis.
• This construct allows the cloning of scFvs or scFv pools via the unique Sphl and EcoRI sites.
• Phage for biopanning applications can be produced using helper phage VCSM13 following standard protocols (Kay et al., 1996).
• engineered phage coat protein and soluble modified scFv were co-expressed from the one- or two-vector systems described above.
• scFv displaying phages were run on SDS PAGE under non-reducing and reducing conditions. Western blot analysis was performed with anti-pBI and anti-Flag Ml antisera.
• Phages were produced according to standard procedures using helper phage VCSM13 (Kay et al., 1996). Phages were pre-incubated in PBS with 5 mM DTT or without DTT (reducing and non-reducing conditions, respectively) for 30 minutes at room temperature before adding SDS loading buffer lacking reducing agents such as DTT or ⁇ -mercaptoethanol. 1 - 5 x 10 10 phages per lane were run on a 4-15% SDS PAGE (BioRad) and blotted onto PVDF membranes.
• the membrane was blocked in MPBST (PBS buffer containing 5% milk powder and 0.05% Tween20) and developed with mouse anti-pHI (1:250 dilution; Mobitec) as primary antibody, anti-mouse-IgG-AP conjugate (1:10000 dilution; SIGMA) as secondary antibody and BCIP/NPT tablets (SIGMA) as substrate.
• MPBST PBS buffer containing 5% milk powder and 0.05% Tween20
• mouse anti-pHI 1:250 dilution; Mobitec
• anti-mouse-IgG-AP conjugate (1:10000 dilution; SIGMA
• BCIP/NPT tablets SIGMA
• the membrane was blocked in MTBST- CaCl 2 (TBS buffer containing 5% milk powder, 0.05% Tween20 and 1 mM CaCl 2 ) and developed with mouse anti-Flag Ml (1:5000 dilution; Sigma) as primary antibody, anti-mouse-IgG-AP conjugate (1:10000 dilution; SIGMA) as secondary antibody and BCIP/NPT tablets (SIGMA) as substrate.
• MTBST- CaCl 2 TBS buffer containing 5% milk powder, 0.05% Tween20 and 1 mM CaCl 2
• mouse anti-Flag Ml (1:5000 dilution; Sigma) as primary antibody
• anti-mouse-IgG-AP conjugate (1:10000 dilution; SIGMA
• BCIP/NPT tablets SIGMA
• phage ELISAs were performed. The analysis was done for the HuCAL scFvs MacI-5 and hag2. For the two-vector system, pMo ⁇ hX7-LHC was co-transformed with pBR-C-gHI, pBR-C-gHICT, pUC-C-gHI and pUC-C-glHCT, respectively.
• Phages were produced according to standard procedures using helper phage VCSM13 and phage titers were determined (Kay et al., 1996). Specific antigen or control antigen (BSA, Sigma #A7906) was coated for 12 hours at 4 °C at an amount of 5 ⁇ g/well in PBS to Nunc Maxiso ⁇ microtiter plates (# 442404) and blocked with PBS containing 5% skimmed milk powder for 2 h.
• BSA Specific antigen or control antigen
• Phages were pre-incubated in PBS containing 2.5% skimmed milk powder, 0.05% Tween 20, as well as 5 mM DTT, where applicable, for 2 h at room temperature before they were applied to the ELISA well coated with antigen at a concentration range between 6.4 x 10 6 and 1 x 10 11 phages per well. After binding for 1 h at RT, unspecifically bound phages were washed away with PBS containing 0.05% Tween 20 and bound phages were detected in ELISA using an anti-M13-HRP conjugate (Amersham Pharmacia Biotech #27-9421-01) and BM blue soluble (Boehringer Mannheim #1484281). Absorbance at 370 nm was measured.
• ELISA signals obtained with the specific antigen were compared to those with the control antigen.
• Specific binding of scFv displaying phages to antigen could be shown for the C-gHI, C-gHICT and C-glX constructs in the one-vector format.
• C-gHI and C-gHICT were also tested and shown to work in both two-vector systems.
• four such ELISAs for scFv MacI-5 are presented in Figures 10-13. In all cases where phage coat proteins are engineered with an additional cysteine residue, ELISA signals are significantly increased compared to the pMo ⁇ hX7-LHC signals where only the scFv carries an additional cysteine.
• pMo ⁇ hl8-C-gIH-hag2-LHC and pM ⁇ hl8-C-gHI-MacI-5-LHC derived phages were mixed at ratios of 1:10 5 (pM ⁇ hl8-C-gIH-hag2-LHC panning) as well as 10 5 :1 (pMo ⁇ hl8-C-gIH- MacI-5-LHC panning). Three rounds of panning were performed on the hag2 and MacI-5 specific antigen, respectively. Phages were prepared by standard procedure and pre-blocked by mixing 1: 1 with PBSTM (PBS, 5% skimmed milk powder, 0.1% Tween20) and incubation for 2 h at RT.
• PBSTM PBS, 5% skimmed milk powder, 0.1% Tween20
• Wells of a Nunc Maxiso ⁇ plate (#442404) were coated with specific antigen (as well as BSA) at a concentration of 5 ⁇ g/well in PBS overnight at 4°C, and subsequently blocked with 400 ⁇ l PBSM (PBS, 5% skimmed milk powder) for 2 h at RT.
• PBSM PBS, 5% skimmed milk powder
• 10 10 pre-blocked phages were applied per well and incubated for 1 h at RT on a microtiter plate shaker. Phage solution was removed and wells were washed 3 times with PBST (PBS, 0.05% Tween20) and 3 times with PBS.
• Bound phages were eluted with 100 mM triethylamine according to standard protocols and used for infection of TGI cells. In addition, residual phages were eluted by direct infection of TGI cells added to the wells. After each round of panning on specific antigen, the ratio of specific to unspecific phages was determined by analysing at least 91 independent infected cells via PCR. The PCR was performed according to standard protocols using single colonies as source of template and oligonucleotides specific for VH CDR3 and VL CDR3 of each scFv as primers.
• the specific clones were enriched to ⁇ 79% (92 out of 117 clones analysed) for the pM ⁇ hl8-C- gIH-hag2-LHC panning and to ⁇ 100% (229 out of 229 clones analysed) for the ⁇ M ⁇ hl8-C- gIH-MacI-5-LHC panning.
• ICAM1 comprising the extracellular part of mature ICAM1 (amino acids 1-454) plus amino acids CGRDYKDDDKHHHHHH containing the M2-Flag and the 6x histidine tag.
• Nl-Macl comprising aa 1-82 of mature gene HI protein of phage M13 containing an additional methionine residue at the N-terminus plus a short linker at the C-terminus (Nl), fused to a polypeptide containing amino acids 149-353 of human CR-3 alpha chain (SWISS-PROT entry PI 1215) plus the C-terminal sequence 1EGRHHHHHH which includes the 6x histidine tag; and (iii) Nl-Np50 comprising Nl fused to a polypeptide containing amino acids 2-366 of human NFKB p50 plus amino acids EFSHHHHHH which include the 6x histidine tag.
• Expression vectors for Nl-Macl and Nl-Np50 are based on vector pTFT74 (Freund et al., 1993) (complete vector sequence of pTFT74-Nl-hag- ⁇ IPM given in Fig. 2). Expression, purification and refolding was done as described (Krebber, 1996; Krebber et al., 1997).
• PBST PBS, 0.05% Tween20
• bound phage were eluted either with 100 mM triethylamine or 100 mM glycine pH 2.2, immediately neutralised with 1 M Tris/HCl pH 7.0 and used for infection of TGI cells.
• residual phages were eluted by direct infection of TGI cells added to the wells.
• Pannings against Nl-Np50 used the complete HuCAL-scFv library (K and ⁇ pools combined), in pannings against Nl-Macl K and ⁇ light chain pools were kept separated.
• the scFvs of the respective pools were subcloned into vector pMo ⁇ h20-C-gIH-scFv-LHC (one-vector format) via the unique Sphl and EcoRI sites. Subsequently, three rounds of cys- display panning were performed. Phages were prepared by standard procedure and pre- blocked by mixing 1:1 with PBSTM (PBS, 5% skimmed milk powder, 0.1% Tween20) and incubated for 2 hrs at RT.
• PBSTM PBS, 5% skimmed milk powder, 0.1% Tween20
• Wells of a Nunc Maxiso ⁇ plate (#442404) were coated with specific antigens at a concentration of 5 ⁇ g/well in PBS overnight at 4°C, and subsequently blocked with 400 ⁇ l PBSM (PBS, 5% skimmed milk powder) for 2 hrs at RT.
• PBSM PBS, 5% skimmed milk powder
• the 1 st round was washed 3x quick and 2x 5 min with PBST and PBS, respectively, the 2 nd round lx quick and 4x 5 min with PBST and PBS, respectively, and the 3 rd round lOx quick and 5x 5 min with PBST and PBS, respectively.
• Bound phages were eluted with 100 mM triethylamine according to standard protocols and used for infection of TGI cells. In addition, residual phages were eluted by direct infection of TGI cells added to the wells.
• Nl-Macl, Nl-Np50 and ICAM-Strep (comprising amino acids 1-455 of mature ICAM1 plus SAWSHPQFEK containing the Strep-tag H) were used as antigens, respectively.
• ICAM-Strep comprising amino acids 1-455 of mature ICAM1 plus SAWSHPQFEK containing the Strep-tag H
• scFvs were subcloned into expression vector pMo ⁇ hX7-FS (Table 1). Subcloning was done in two steps.
• scFv fragments were isolated from pM ⁇ h20-C-gIH-scFv-LHC via A ZH and EcoRI, then the fragments were re- digested with Sphl and cloned into the EcoRl/Sphl digested pMo ⁇ hX7-FS vector. This procedure ensured that only scFvs from vector pMo ⁇ h20-C-gIH-scFv-LHC were subcloned and excluded any contamination with scFvs from a conventional display or expression vector. Expression of the scFvs and their testing in ELISA against the respective antigens was done according to standard procedures.
• the affinity of some of the selected scFvs was determined in Biacore and Kd values in the range of 1 nM to 2.2 ⁇ M were determined. These results are similar to the enrichment factors and affinities obtained in a conventional panning of the respective pools performed in parallel. Some of the scFvs were selected independently via cys-display as well as conventional panning.
• phage display libraries When screening phage display libraries in biopanning the problem remains how to best recover phages which have bound to the desired target. Normally, this is achieved by elution with appropriate buffers, either by using a pH- or salt gradient, or by specific elution using soluble target. However, the most interesting binders which bind with high affinity to the target might be lost by that approach.
• One option with engineered cys-display phages is that the complexes of target and specific bacteriophages can be treated with reducing agents, e.g. by incubation with DTT, to cleave the disulfide bond between scFv and phage coat protein and to recover the specific bacteriophage particles.
• Pannings of pre-selected pools against Nl-Macl were performed according to the protocol described above. Phages were eluted either according to the standard protocol with 100 mM triethylamine and a direct infection of TGI cells by residual phages, or by incubation of the wells with 20 mM DTT in Tris buffer pH 8.0 for 10 min. After each round of panning the pool of selected scFvs was subcloned into expression vector pMo ⁇ hX7-FS according to the two step procedure described above, and the number of Nl-Macl specific scFvs was determined in ELISA.
• Example 2.1 shows that functional single chain fragments can be displayed on engineered phages via disulfide bonds.
• the cysteine was engineered at different positions of the Fab antibody fragment. These Fabs were co-expressed in the same bacterial cell together with engineered full length pIH based on a two- vector system.
• Heavy and light chains of the Fab fragment were expressed from a dicistronic phagemid under control of the lac promotor/operator region.
• the first expression cassette comprises the signal sequence ompA and the variable and constant domain of the light chain
• the second expression cassette comprises the signal sequence phoA and the variable and constant domain of the heavy chain. Heavy and light chain are not linked via a disulfide bond. Modules containing the engineered cysteine were located at the C-terminus of either the light or the heavy chain.
• Table 6 Several constructs differing in the amino acid composition of the modules were compared and are summarised in Table 6. As an example the complete vector sequence of pMo ⁇ hXIO-Fab-VL-LHC-VH-FS coding for the modified Fab MacI-5 and the respective vector map are given in Figure 16a+b.
• Plasmid pBR-C-gHI Two different plasmids were used for expression of full length pIH. Plasmid pBR-C-gHI was already described above.
• the respective expression cassette comprises the signal sequence ompA, amino acids DYCDIEF and the pIH ORF under control of the lactose promotor/ operator region (Table 3, Figure 6).
• plasmid pBAD-SS-C-gHI was used.
• the respective expression cassette comprises the signal sequence of pLT, amino acids TMACDIEF and the pEH ORF under control of the arabinose promotor/operator region (Table 3).
• the fragment coding for the engineered cysteine plus pIH was amplified from pUC-C-gHI via PCR introducing the restriction sites Ncol and HmdHI and cloned into the commercially available vector pBAD/gHI A (Invitrogen).
• the plasmids pBR-C-gHI or pBAD-SS-C-glH were co-transformed with the respective pMo ⁇ hXIO-Fab phagemids expressing the modified Fab into E.coli TGI selecting for both antibiotic markers. Description of the Fab - antigen interactions
• Fabs Macl-A8 and ICAM1-C8 were isolated directly from one of the HuCAL-Fab libraries.
• Clone Macl-A8 was selected against antigen Mad-Strep, which comprises an N-terminal methionine, amino acids 149-353 of human CR-3 alpha chain (SWISS-PROT entry PI 1215) and amino acids SAWSHPQFEK which include the Strep-tag H (Schmidt et al., 1996). Expression and purification were done according to Schmidt & Skerra (1994). Nl-Macl was used as corresponding antigen for ELISAs.
• Nl-Macl is described above, and comprises an N-terminal methionine, amino acids 1-82 of mature gene HI protein of phage M13 plus a short linker (Nl), amino acids 149-353 of human CR-3 alpha chain (SWISS-PROT entry PI 1215) and amino acids lEGRHHHHHH which include the 6x histidine tag.
• Clone ICAM1-C8 was selected against antigen ICAM1 described above, which comprises the extracellular part of mature ICAM1 (amino acids 1- 454) plus amino acids CGRDYKDDDKHHHHHH containing the M2-Flag and the 6x histidine tags. The same antigen was used for ELISA assays as well as in the doped library experiment.
• Phages were produced using helper phage VCSM13 following standard protocols (Kay et al., 1996). In addition to helper phage proteins, engineered phage coat protein and soluble modified Fab were co-expressed from the two-vector system. Phages were pre-incubated in PBS with or without 20 mM DTT (reducing and non-reducing conditions, respectively) for 1 h at room temperature before adding SDS loading buffer lacking reducing agents such as DTT or ⁇ -mercaptoethanol. lx 10 10 phages per lane were run on a 12 % SDS PAGE (BioRad) and blotted onto nitrocellulose membranes (Schleicher & Schuell).
• the membrane was blocked in MTBST (50 mM Tris buffer pH 7.4, containing 5% milk powder and 0.05% Tween20) and developed with mouse anti-pEQ (1:250 dilution; Mobitec) as primary antibody, anti-mouse-IgG-HRP conjugate (1:5000 dilution; SIGMA) as secondary antibody and BM Blue POD precipitating (Roche #1442066) as substrate.
• MTBST 50 mM Tris buffer pH 7.4, containing 5% milk powder and 0.05% Tween20
• mouse anti-pEQ 1:250 dilution; Mobitec
• anti-mouse-IgG-HRP conjugate (1:5000 dilution; SIGMA
• BM Blue POD precipitating (Roche #1442066) as substrate.
• kappa light and lambda light chain For the detection of the heavy chain, kappa light and lambda light chain the primary antibodies anti-Fd (1:5000 dilution; The binding site PC075), anti-human kappa (1:5000 dilution; Sigma K-4377) and anti-human lambda (1:500 dilution, Sigma L-6522) were used, respectively.
• free protein HI (SH-pHI and/or pHI) can be detected for all expression systems both under reducing and non-reducing conditions ( Figures 17 and 18).
• a signal migrating at the height of a hetero-dimer of light chain and protein HI (VL-CL-SS-pHI) appears under non- reducing conditions.
• pHI-SS-pHI a band migrating at the height expected for disulfide bonded protein HI dimers
• phagemids expressing the modified Fab were co-transformed with pBR-C-glH and phage production was performed under standard conditions (Kay et al., 1996).
• Conventional Fab display phages (pM ⁇ hl8-Fab) served as positive control
• a phagemid expression vector for expression of non-engineered Fab (pMo ⁇ hX9-Fab-FS) served as negative control.
• Specific antigen or control antigen (BSA, Sigma #A7906) was coated for 12 hours at 4 °C at an amount of 5 ⁇ g/well in PBS to Nunc Maxiso ⁇ microtiter plates (# 442404) and blocked with PBS containing 5 % skimmed milk powder, 0.05 % Tween 20 for 1 h. Phages were pre-incubated in PBS containing 5 % skimmed milk powder, 0.05 % Tween 20, and 10 mM DTT where applicable for 1 h at room temperature before they were applied to the ELISA well coated with antigen at a concentration range between lx 10 8 and 1 x 10 10 phages per well.
• Engineered phages displaying ICAM1-C8 and Macl-A8 were mixed at ratios of 1:10 5 . Three rounds of panning were performed on the ICAM1 antigen. Phages were prepared by standard procedure, pre-blocked by mixing 1:1 with PBSTM (PBS, 5 % skimmed milk powder, 0.1 % Tween 20) and incubated for 2 hrs at RT. Wells of a Nunc Maxiso ⁇ plate (#442404) were coated with specific antigen at a concentration of 5 ⁇ g/well in PBS overnight at 4°C, and subsequently blocked with 400 ⁇ l PBSM (PBS, 5 % skimmed milk powder) for 2 hrs at RT.
• PBSTM PBS, 5 % skimmed milk powder, 0.1 % Tween 20
• the ratio of specific to unspecific phages was determined by analysing at least 92 independent infected cells via PCR.
• the PCR was performed according to standard protocols using single colonies as source of template and oligonucleotides specific for the lambda light chain (priming in framework 4), the kappa light chain (priming in framework 3) and a vector sequence upstream of the Fab fragment (commercial M13-rev primer, NEB) as primers. Fragments of roughly 420 bp length were expected for lambda Fabs (ICAM1-C8) and 290 bp for kappa Fabs (Macl-A8).
• 61 % positive clones 57 out of 93 clones analysed
• were obtained which could be enriched to 100 % (92 out of 92 clones analysed) after the third round.
• Escherichia coli Antibody Engineering. A Practical Approach (Ed. C.A.K.
• SIP Selectively-infective phage
• Table 1 Amino acid sequence of ORF modules between the EcoRI and HmdHI sites of vectors pMorphX7-hag2-FS, pMorphX7-hag2-LH, pMorphX7-hag2-LCH and pMorphX7-hag2-LHC
• Nl-Macl Nl-Np50: number of clones after one round of conventional panning
• ICAM1 diversity of the light chain optimised pool.
• b number of EUSA positives of the respective pre-selected pools.
• the engineered cysteine is written in bold

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Genetics & Genomics (AREA)
• Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Microbiology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Zoology (AREA)
• Biophysics (AREA)
• Wood Science & Technology (AREA)
• Virology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Plant Pathology (AREA)
• Gastroenterology & Hepatology (AREA)
• Physics & Mathematics (AREA)
• Crystallography & Structural Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Processes Of Treating Macromolecular Substances (AREA)

Priority Applications (12)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (2)

Family

ID=26070571

Family Applications (1)

Country Status (13)

Cited By (102)

Families Citing this family (34)

Family Cites Families (20)

• 2000
  • 2000-07-20 ES ES00945941T patent/ES2327382T3/es not_active Expired - Lifetime
  • 2000-07-20 DE DE60041119T patent/DE60041119D1/de not_active Expired - Lifetime
  • 2000-07-20 EP EP08153541A patent/EP1990409A3/en not_active Withdrawn
  • 2000-07-20 EP EP00945941A patent/EP1144607B1/en not_active Expired - Lifetime
  • 2000-07-20 AU AU59864/00A patent/AU781396B2/en not_active Expired
  • 2000-07-20 JP JP2001511164A patent/JP4312403B2/ja not_active Expired - Lifetime
  • 2000-07-20 CA CA2347973A patent/CA2347973C/en not_active Expired - Lifetime
  • 2000-07-20 WO PCT/EP2000/006968 patent/WO2001005950A2/en not_active Ceased
  • 2000-07-20 IL IL14202500A patent/IL142025A0/xx unknown
  • 2000-07-20 PT PT00945941T patent/PT1144607E/pt unknown
  • 2000-07-20 AT AT00945941T patent/ATE417925T1/de active
  • 2000-07-20 DK DK00945941T patent/DK1144607T5/da active
• 2001
  • 2001-03-14 IL IL142025A patent/IL142025A/en active IP Right Grant
  • 2001-03-15 US US09/809,517 patent/US6753136B2/en not_active Expired - Lifetime
  • 2001-03-19 NO NO20011386A patent/NO331199B1/no not_active IP Right Cessation
• 2003
  • 2003-09-10 US US10/658,752 patent/US7785859B2/en not_active Expired - Fee Related
• 2007
  • 2007-02-28 US US11/680,259 patent/US20070292947A1/en not_active Abandoned

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events